Skip to main content
. Author manuscript; available in PMC: 2023 Aug 1.
Published in final edited form as: Nat Nanotechnol. 2022 Nov 24;18(2):193–204. doi: 10.1038/s41565-022-01266-2

Fig. 2: Development and biophysical characterization of PMBOP-CP-based nanocarrier for codelivery of siXkr8 and FuOXP.

Fig. 2:

a: A schematic diagram of the protocol for the preparation of FuOXP/siRNA-coloaded PMBOP-CP NPs. b: CMC of PMBOP polymer. c: Biophysical characterization of PMBOP/FuOXP mixed micelles at various carrier/drug ratios (w/w). N=3 replicates. d: Gel retardation assay of PMBOP/FuOXP/siRNA complexes at various N/P ratios. e: Sizes and zeta potentials of PMBOP/FuOXP/siRNA complexes at various N/P ratios. N=3 replicates. f: Sizes and zeta potentials of FuOXP/siRNA-coloaded PMBOP-C NPs (coated with CS alone) at various N/P/S ratios. N=3 replicates. g: Sizes and zeta potentials of FuOXP/siRNA-coloaded PMBOP-CP NPs (coated with a mixture of CS and PEG-CS) at various N/P/S(CS)/S(PEG-CS) ratios. N=3 replicates. h: Spherical morphology of PMBOP-CP NPs with and without coloaded siRNA by cryo-EM. Scale bar, 100 nm. i: Cumulative FuOXP release from PMBOP-CP NPs with or without siRNA complexation in PBS or murine serum. N=3 replicates. j: Protection of siRNA in PMBOP-CP NPs against the digestion by RNAse. Data are presented as mean ± SEM and statistical analysis was performed by one-way analysis of variance (ANOVA) with Tukey post hoc test for comparison in i. Data are representative of 2 independent experiments in h and 3 independent experiments in b-g, i and j.